Andrew Guggenhime Sells 8,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $83.85, for a total transaction of $670,800.00. Following the completion of the sale, the chief financial officer now owns 109,491 shares of the company’s stock, valued at $9,180,820.35. This trade represents a 6.81 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Andrew Guggenhime also recently made the following trade(s):

• On Tuesday, January 21st, Andrew Guggenhime sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $86.51, for a total transaction of $692,080.00.
• On Wednesday, December 18th, Andrew Guggenhime sold 8,000 shares of Vaxcyte stock. The stock was sold at an average price of $88.78, for a total transaction of $710,240.00.

Vaxcyte Trading Down 3.3 %

Vaxcyte stock opened at $79.74 on Friday. The stock has a market cap of $9.94 billion, a P/E ratio of -17.33 and a beta of 0.98. The company has a fifty day simple moving average of $85.61 and a 200-day simple moving average of $94.62. Vaxcyte, Inc. has a 12-month low of $58.10 and a 12-month high of $121.06.

Institutional Investors Weigh In On Vaxcyte

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Blue Trust Inc. lifted its position in Vaxcyte by 33.5% in the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after acquiring an additional 93 shares during the last quarter. Nisa Investment Advisors LLC lifted its position in Vaxcyte by 5.2% in the third quarter. Nisa Investment Advisors LLC now owns 2,209 shares of the company’s stock valued at $252,000 after acquiring an additional 110 shares during the last quarter. CIBC Asset Management Inc lifted its position in Vaxcyte by 3.6% in the third quarter. CIBC Asset Management Inc now owns 3,136 shares of the company’s stock valued at $358,000 after acquiring an additional 110 shares during the last quarter. Bridgefront Capital LLC lifted its position in Vaxcyte by 4.2% in the fourth quarter. Bridgefront Capital LLC now owns 4,244 shares of the company’s stock valued at $347,000 after acquiring an additional 172 shares during the last quarter. Finally, Smartleaf Asset Management LLC lifted its position in Vaxcyte by 188.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock valued at $33,000 after acquiring an additional 260 shares during the last quarter. 96.78% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have commented on PCVX. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Needham & Company LLC restated a “buy” rating and issued a $14.00 price target on shares of Vaxcyte in a research note on Tuesday, February 11th. Finally, The Goldman Sachs Group began coverage on shares of Vaxcyte in a research note on Friday, December 20th. They issued a “buy” rating and a $135.00 price target for the company. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $127.71.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.